Rybelsus is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist medication approved for the treatment of type 2 diabetes mellitus. It helps regulate blood sugar levels by stimulating insulin secretion, reducing glucagon release, and slowing gastric emptying. Taken once daily in tablet form, Rybelsus supports improved glycemic control when combined with diet and exercise. This medication may also aid in weight loss and reduce the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. Patients should follow healthcare provider instructions for dosing and administration. Common side effects include nausea, diarrhea, decreased appetite, and potential risk of pancreatitis.